-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を10ドルから6ドルに引き下げます。予想を下回る第1四半期決算発表を受け、LCID株の投資判断は「ホールド」を維持します。2026年の調整後EPS予想を-12.70ドルから-12.00ドルに、2027年の調整後EPS予想を-11.45ドルから-11.10ドルに修正します。LCIDの第1四半期調整後EPSは-2.82ドルで、市場予想の-2.04ドルを大きく下回りました。第1四半期の売上高は、価格上昇に牽引され20%増の2億8,250万ドル(市場予想を7,600万ドル下回る)となりましたが、車両販売台数は1%減の3,093台でした。今回の発表で、LCIDは2026年の車両生産台数に関する以前のガイダンスである2万5000~2万7000台(2025年の生産台数1万7840台を上回ることを示唆)について、何ら最新情報を提供しなかった。我々の見解では、LCIDの資金流出の加速と在庫の増加は、継続的なリスクを示唆している。競争の激しい高級EV市場で確固たる地位を確立しようとする同社にとって、多額の資金需要を管理しながら持続的な成長を達成できるかどうかが依然として重要な課題である。しかしながら、先月実施された15億ドルの資金調達は、流動性確保の猶予期間を延長するのに役立っている。
Related Articles
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%